Travere Therapeutics (NASDAQ: TVTX) reported Q3 EPS of $0.59, $0.88 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $164.9 million versus the consensus estimate of $105.57 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.